Kura Oncology, Inc. (KURA)
| Market Cap | 872.65M +67.2% |
| Revenue (ttm) | 71.64M +5.4% |
| Net Income | -294.57M |
| EPS | -3.35 |
| Shares Out | 88.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 802,565 |
| Open | 9.49 |
| Previous Close | 9.57 |
| Day's Range | 9.46 - 9.67 |
| 52-Week Range | 5.45 - 12.49 |
| Beta | 0.38 |
| Analysts | Strong Buy |
| Price Target | 31.17 (+217.09%) |
| Earnings Date | Aug 12, 2026 |
About KURA
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional n... [Read more]
Financial Performance
In 2025, Kura Oncology's revenue was $67.48 million, an increase of 25.24% compared to the previous year's $53.88 million. Losses were -$278.67 million, 60.2% more than in 2024.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for KURA stock is "Strong Buy." The 12-month stock price target is $31.17, which is an increase of 217.09% from the latest price.
News
Kura Oncology announces publication in Blood on ziftomenib binding profile
Kura Oncology (KURA) announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and preclinical development of ziftomenib, ...
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity
– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology to Report Second Quarter Financial Results
SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, toda...
Kura Oncology Transcript: Study update
Darlifarnib plus cabozantinib in advanced RCC showed 33%-50% objective response rates and a median PFS of 13 months in cabozantinib-naive patients, with a manageable safety profile. The combination outperformed historical benchmarks and supports further development in both naive and TKI-exposed populations.
Kura Oncology Press release: Study update
Kura Oncology issued a press release on July 27, 2026, disclosing material business information to investors.
Kura Oncology Slides: Study update
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on July 27, 2026.
Kura Oncology announces durable activity of darlifarnib combination in ccRCC
Kura Oncology (KURA) announced updated Phase 1a results from the ongoing FIT-001 clinical trial demonstrating encouraging and durable clinical activity of darlifarnib plus cabozantinib in cabozantinib...
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
– Response rates up to 50% across evaluated dose levels and median PFS of 13 months observed in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients –
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib's Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
– Oral presentation will feature updated data from the FIT-001 Phase 1a study of darlifarnib plus cabozantinib in cabozantinib-naïve, advanced ccRCC patients –
Kura Oncology Transcript: Status update
Ziftomenib plus 7+3 in newly diagnosed AML achieved high CR and MRD negativity rates, with durable responses and favorable safety, supporting ongoing phase III trials. The combination may reduce transplant needs and expand market potential, with robust early commercial momentum.
Kura Oncology Press release: Status update
Kura Oncology issued a press release on June 12, 2026, disclosing material business information to investors.
Kura Oncology Slides: Status update
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 12, 2026.
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
– 12-month OS rate 94% among NPM1-m AML patients and 71% among KMT2A-r AML patients in single-arm KOMET-007 trial –
Kura Oncology Transcript: Investor update
Darlifarnib combined with RAS inhibitors shows promising efficacy and manageable safety in KRAS-driven tumors, with particularly strong results in pancreatic cancer. A platform trial will evaluate multiple combinations across tumor types, supporting broad applicability and future registrational studies.
Kura Oncology Press release: Investor update
Kura Oncology issued a press release on June 3, 2026, disclosing material business information to investors.
Kura Oncology Slides: Investor update
Kura Oncology has posted slides in relation to its latest quarterly earnings report, which was published on June 3, 2026.
Kura reports data supporting darlifarnib potential for KRAS-mutant cancers
Kura Oncology (KURA) highlighted new clinical and translational data supporting darlifarnib as a potential foundational combination platform for KRAS-mutant cancers and other targeted therapy settings...
Kura Oncology Highlights Darlifarnib's Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
– Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve...
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
– 87% ORR and 70% CRc in venetoclax-naïve and 48% ORR and 24% CRc in venetoclax-experienced patients at the recommended 600 mg once-daily dose – – Central MRD negativity in 75% of CRc responders with ...
Kura Oncology Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA
KOMZIFTI's launch in relapsed/refractory NPM1-mutant AML is exceeding expectations, with strong clinical data supporting its use as a combinable backbone. High response rates and robust MRD negativity in AML trials, along with promising results in solid tumors, position the pipeline for significant growth.
Kura Oncology Proxy statement: Proxy filing
Kura Oncology filed a proxy statement on May 26, 2026, providing details for shareholder voting and corporate governance matters.
Kura Oncology reports first-in-human data from the FIT-001 clinical trial
Kura Oncology (KURA) reported compelling first-in-human data from the FIT-001 clinical trial of its next-generation farnesyl transferase inhibitor, or FTI, darlifarnib in combination with adagrasib in...
Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors
– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients –
Kura Oncology to Present at TD Cowen 7th Annual Oncology Innovation Summit
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA) today announced its participation in the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. Kura ma...